Name: Latest research reports of Alembic Pharmaceuticals Ltd. authored by ICICI Direct and published by - Trendlyne research reports.
Item: Alembic Pharmaceuticals Ltd.
Rating: 3
Author: ICICI Direct

Summary	Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report	Discuss
	02 Oct 2025	Alembic Pharma	Consensus Share Price Target	904.30	1056.64	-	16.85	buy	pdf Detailed Estimates
	02 Feb 2023	Alembic Pharma	ICICI Direct Target	904.30	550.00	540.95 (67.17%)	Target met	Hold	pdf post cache	Broker Report Alembic Pharmaceuticals ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	02 Feb 2023	Alembic Pharma	ICICI Securities Limited Reco Target	904.30	653.00	539.65 (67.57%)	Target met	Buy	pdf post cache	Broker Report Revenue outperforms; profits disappoint ICICI Securities Limited Alembic Pharma’s (Alembic) Q3FY23 overall performance was a mixed bag. Revenue grew 18.7% YoY to Rs15.1bn (I-Sec: Rs14.1bn). India business grew 11.7% YoY. API revenue was up 64.6% YoY (+10.9% QoQ) to Rs.3.3bn, partially supported by a bulk order in a certain CMO contract. pdf Copy Link Share on Share on Share on Share on Alert
	15 Nov 2022	Alembic Pharma	ICICI Securities Limited Reco Target	904.30	695.00	646.30 (39.92%)	Target met	Accumulate	pdf post cache	Broker Report Q2 sees recovery; growth could accelerate ICICI Securities Limited Alembic Pharma’s (Alembic) Q2FY23 performance was broadly in line with our estimates. Revenue grew 14.1% YoY to Rs14.8bn (I-Sec: Rs14.4bn). India business (excl. one-time benefits) grew ~11% YoY. pdf Copy Link Share on Share on Share on Share on Alert
	14 Nov 2022	Alembic Pharma	ICICI Direct Reco Target	904.30	625.00	640.00 (41.30%)	Target met	Hold	pdf post cache	Broker Report Alembic Pharmaceuticals ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	13 Nov 2022	Alembic Pharma	Motilal Oswal Target	904.30	570.00	640.00 (41.30%)	Target met	Sell	pdf post cache	Broker Report Strong execution drives earnings beat Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
	05 Aug 2022	Alembic Pharma	Motilal Oswal Reco Target	904.30	590.00	672.65 (34.44%)	Target met	Sell	pdf post cache	Broker Report Successful compliance at its Injectables site key to an earnings revival Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
	05 Aug 2022	Alembic Pharma	ICICI Securities Limited Reco Target	904.30	641.00	702.95 (28.64%)	Target met	Sell	pdf post cache	Broker Report Lowest margin in several years ICICI Securities Limited Alembic Pharma’s (Alembic) Q1FY23 performance was below our estimates due to sharp fall in US sales, which declined 37.3% QoQ to US$47mn on high base in Q4FY22 owing to inventory restocking, lower offtake during the quarter and continuous price erosion in the base business. India business (ex-covid) grew ~20% YoY. pdf Copy Link Share on Share on Share on Share on Alert
	05 Aug 2022	Alembic Pharma	ICICI Direct Reco Target	904.30	590.00	672.65 (34.44%)	Target met	Sell	pdf post cache	Broker Report Alembic Pharmaceuticals ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	04 May 2022	Alembic Pharma	ICICI Direct	904.30	720.00	733.85 (23.23%)	Target met	Hold	pdf post cache	Broker Report Alembic Pharmaceuticals ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	02 May 2022	Alembic Pharma	BOB Capital Markets Ltd. Reco Target	904.30	770.00	733.85 (23.23%)	Target met	Hold	pdf post cache	Broker Report Alembic Pharma (HOLD): Mixed quarter; cut to HOLD amid rising margin pressure BOB Capital Markets Ltd. Q4 revenue growth at 11% YoY led by broad-based domestic uptick and 17% growth in the US; ROW declined 19% YoY pdf Copy Link Share on Share on Share on Share on Alert
more loading

30.65% Fall from 52W High

Alembic Pharmaceuticals Ltd. share price target

Alembic Pharmaceuticals Ltd. has an average share price target of 1001. The consensus estimate represents an upside of 10.69% from the last price of 904.30. View 10 reports from 4 analysts offering long-term price targets for Alembic Pharmaceuticals Ltd..

Alembic Pharmaceuticals

Revenue outperforms; profits disappoint

Q2 sees recovery; growth could accelerate

Alembic Pharmaceuticals

Strong execution drives earnings beat

Successful compliance at its Injectables site key to an earnings revival

Lowest margin in several years

Alembic Pharmaceuticals

Alembic Pharmaceuticals

Alembic Pharma (HOLD): Mixed quarter; cut to HOLD amid rising margin pressure

Advisor Screeners